Drug Utilization Review Board
Meeting Minutes, Open Session
October 19, 2022 10:00am – 2:00pm

Drug Utilization Review Board Due to COVID-19, this meeting was held virtually.	**Board Members:** Moneeshindra Mittal, MD, Chair James Backes, PharmD, Interim Chair Gregory Burger, PharmD, CPPS, FASHP, EMT Daryl Callahan, D.O, MSS Jennifer Clair, MD Kristen Powell, PharmD Michele Reisinger, DNP, APRN, FNP-BC Arthur Snow, MD Cori Durall, PharmD **KDHE-DHCF/Contractor Staff:** Annette Grant, RPh Victor Nguyen, PharmD Sridevi Donepudi, MD *(Absent)* Carol Arace, Administrative Specialist **MCO Staff:** Mark DeMary, RPh, Aetna Better Health of Kansas Angie Yoo, PharmD, Sunflower State Health Plan Sunny Bounyalath, PharmD, UnitedHealthcare Community Plan **Gainwell Technology Staff:** Karen Kluczykowski, RPh Kathy Kaesewurm, RN, BSN Christina Faulkner, PharmD, BCPS Harry Vu, PharmD	**Public attendees:** Jordan Brazeal, PharmD, Erin Hohman, Alina Triasucheva, Anuj Patel, Cheryl Donahue, Corey O'Brien, Dominick De wolf, Don McCaffrey, Madison Elliott, Sara Hovland, Jordan Feuerborn Mary Shefchyk, Rhonda Clark, Stephanie Michel, Tami Sova, Sara Sanders, Jenny Carrell, Marc Parker Lee Ward, Robert Kilo, Jim Baumann Donna Osterlund, Joe Payne, Jordon Wild [Non-identified participants are not listed.]

TOPIC	DISCUSSION	DECISION
I. Call to Order A. Introductions B. Announcements	**Call to Order:** Dr. Mittal called the meeting to order at 10:09am and proceeded to take roll call for the board members. **Introductions:** None. **Announcements:** None.	

TOPIC	DISCUSSION	DECISION
II. Old Business A. Review and Approval of the July 20, 2022 Meeting Minutes	**Board Discussion:** Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Snow moved to approve the minutes. Dr. Burger second the motion. Dr. Mittal abstained due to being absent. Motion to approve was otherwise carried unanimously.
III. New Business A. Executive Sign-off – Approval of Process	**Background:** This process is intended to streamline the Board's approval procedures for simple and standard updates to existing PA criteria. These changes may include additions of new formulations/strengths/dosing regimens/biosimilars where indications are the same. **Public comment:** Sara Hovland (BMS) pointed out that public comment was not currently included. Erin Hohman (Abbvie) yielded her time back to the Board. **Board Discussion:** The Board asked whether or not criteria would be presented. The State clarified that the Board would review the advanced copies of the drafts before the meeting and that the descriptions for each agenda items would be listed on the meeting's agenda, as usual. To facilitate public comment, the Board recommended to remove and separately address any agenda item where a conflict of interest form was received. The State concurred and also noted that the agenda would be updated to reflect any changes before each meeting. The Board recommended a short-term approval of 6 months, at which point this process would be re-evaluated and fine-tuned.	Dr. Snow moved to approve as amended. Dr. Powell second the motion. Motion to approve as amended was carried unanimously.
B. Executive Sign-off Agenda Items	**Background:** Plaque Psoriasis was the only agenda item removed to be discussed separately. The remaining 4 agenda items include: Ankylosing Spondylitis Agents, Enzyme Replacement Therapy, Minimum Requirements Prior Authorization, and Spinal Muscular Atrophy Agents. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Backes second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
C. <u>Revised Prior Authorization (PA) Criteria</u> 1. Growth Hormone Agents (previously Somatropin Products)	**Background:** This revision updates criteria for initiation of growth hormone in pediatric populations. **Public comment:** None. **Board Discussion:** The Board commended the State on efforts to revise and update the criteria. The Board recommended to include the summary table of criteria for other pediatric indications that the State presented as visual aid.	Dr. Powell moved to approve as amended. Dr. Callahan second the motion. Motion to approve as amended was carried unanimously.
2. Weight Loss Agents	**Background:** This revision includes an update to indicated age groups for Qsymia® and revisions to pediatric criteria. **Public comment:** Corey O'Brien (Novo Nordisk) yielded his time back to the Board. **Board Discussion:** None.	Dr. Clair moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
3. Synagis® (palivizumab)	**Background:** This revision updates the criteria to allow for providers to submit data for evaluation for when local trends do not align with the CDC National Respiratory and Enteric Virus Surveillance System. **Public comment:** None. **Board Discussion:** The Board felt that it would be to the benefit of the patients if more laboratories would voluntarily submit their RSV data.	Dr. Backes moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
4. Plaque Psoriasis Agents	**Background:** This revision includes the addition of Sotyktu™ to the list of agents requiring prior authorization, updates the indicated age groups for Stelara® and Cosentyx®, and updates a blanket statement regarding other FDA-approved indications. **Public comment:** Sara Hovland (BMS) was available for questions on Sotyktu™ and yielded her time back to the Board.	Dr. Snow moved to approve. Dr. Callahan second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
	Board Discussion: None	
D. <u>New Prior Authorization (PA) Criteria</u> 1. Beta-Thalassemia Agents	**Background:** Zynteglo® (betibeglogene autotemcel) is a hematopoietic stem cell-based gene therapy recently approved for the treatment of transfusion dependent β-thalassemia. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines. **Public comment:** None. **Board Discussion:** The Board asked why Zynteglo® was no longer marketed in Europe and whether this therapy was administered inpatient or outpatient. The State explained that Zynteglo® was withdrawn from the European market simply due to the €1.575 million cost and that administration of the therapy was expected to be inpatient at a Center of Excellence. The State also elaborated that the focus of the criteria was appropriate patient selection. The Board asked if there was any anticipation on a number of patients to be treated. The State replied that there was at least one member that receives multiple transfusions that might meet the criteria.	Dr. Clair moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
2. Thyroid Eye Disease Agents	**Background:** Tepezza® (teprotumumab) is an insulin-like growth factor-1 receptor inhibitor (IGF-1R) approved for the treatment of thyroid eye disease, also known as Graves' Orbitopathy. The prior authorization criteria are being proposed to ensure appropriate use based upon FDA-approved labeling information and clinical guidelines. **Public comment:** Anuj Patel (Horizon) was available for questions on Tepezza® and yielded his time back to the Board. **Board Discussion:** None.	Dr. Snow moved to approve. Dr. Burger second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
E. Tentative Agenda Items – MHMAC Meeting (October 18, 2022) 1. Antidepressant Medications – Safe Use for All Ages	**Background:** This revision adds Auvelity™ with step therapy, while removing Viibryd® from step therapy due to recent generic launches. **Public comment:** None **Board Discussion:** The Board asked for a reminder on whether or not changes could be made. The State confirmed the Board could only approve or disapprove and that suggestions on changes would need to be brought back to the Committee for review at their next meeting.	Dr. Powell moved to approve. Dr. Backes second the motion. Motion to approve was carried unanimously.
F. Miscellaneous Items 1. Fee-for-Service Annual Program Assessment	**Background:** Dr. Faulkner presented the annual program assessment for the Medicaid fee-for-service population to show drug trends over the past state fiscal year. **Board Discussion:** None.	
2. Managed Care Annual Program Assessment i. Aetna Individual Report ii. Sunflower Individual Report iii. UnitedHealthcare Individual Report	**Background:** • Mark DeMary, RPh, presented Aetna's annual DUR Program activity report. • Dr. Yoo presented Sunflower's annual DUR Program activity report. • Dr. Bounyalath presented UnitedHealthcare's annual DUR Program activity report. **Public comment:** None **Board Discussion:** None	N/A
IV. Adjourn	The meeting adjourned at 12:26pm	Dr. Snow motioned to approve. Dr. Callahan seconded the motion. Motion to adjourn was carried unanimously.

The next DUR Board meeting is scheduled for January 18, 2023.
*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion.
Informal comments will be accepted from members of the audience at various points in the agenda.
All approved PA criteria are posted to the KDHE website: https://www.kdhe.ks.gov/206/General-Clinical-Prior-Authorization